Ilya Petrou, M.D.
Lesion-directed topical therapy safe for actinic keratosis
A new topical therapy combining low-dose 5-fluorouracil (5-FU) with salicylic acid is proving very effective in the treatment of actinic keratosis (AK), particularly in more difficult to treat advanced hyperkeratotic AK lesions, study results show.
Anabolic androgenic steroid use, abuse on the rise
Use and abuse of anabolic androgenic steroids is on the rise, not just among athletes but also in the general population. Because dermatological manifestations are often the first indications of such behavior, dermatologists must know the common side effects associated with these drugs so they can treat the hallmark symptoms of abuse while educating patients.
Severe urticaria cases manageable with novel treatment options
Chronic urticaria can be difficult to treat, but new and evolving therapeutic options can effectively manage symptoms. Treating the cause of chronic urticaria is one of the primary goals of therapy, but very often the cause is not found. Chronic idiopathic urticaria is the diagnosis given to those patients where the etiology remains unknown.
Closely monitoring xeroderma pigmentosum key to disease management
The early diagnosis of xeroderma pigmentosum (XP) is not only crucial for the timely implementation of therapeutic regimens in patients suffering from this disease; it's also key to keeping the development of cutaneous cancers to a minimum.
New botulinum toxin expected to challenge cosmetic market leaders
The safety and dose equivalency of PurTox (Mentor) should place the botulinum toxin head-to-head with Botox when it reaches the U.S. market, according to a European physician who has experience using the pure toxin there. The newcomer, PurTox, is said to be equivalent to the universal comparator Botox (onabotulinumtoxinA, Allergan) in terms of dosing, and, therefore, represents a potential future nemesis for Botox and other toxins on the market.
Immunomodulatory antibodies for melanoma treatment prove promising
Novel immunomodulatory antibodies such as ipilimumab (Bristol-Myers Squibb) and other experimental treatment options such as melanoma vaccines, chemotherapy agents (Abraxane, Celgene) and targeted drug therapies (BRAF inhibitors) are proving effective in the treatment of patients with late-stage melanoma, offering increased hope in the continuing battle against this deadly skin cancer.
Multi-pronged strategy controls recalcitrant dermatitis in children
Dermatitis in children can be challenging to treat, particularly when commonly used treatment regimens fail. According to one expert, a multi-pronged treatment strategy is the best approach to help clear symptoms and control disease.
Research competition, market needs before purchasing aesthetic technologies
Before investing in aesthetic devices, physicians need to do their homework and carefully weigh the pros and cons of each device and attend lectures focused on various aesthetic devices and technologies. This approach may help them ultimately choose an aesthetic device that is right for them and their patients.
Radiofrequency for noninvasive body contouring turns up the heat for results
Among the various aesthetic device technologies used to treat skin laxity, cellulite and achieve circumference reduction, radiofrequency (RF) appears to be one of the most efficacious energy sources currently available.
Topical imiquimod successful in treating lentigo maligna, in certain settings
The use of topical imiquimod can be beneficial in the treatment and management of lentigo maligna (LM), but knowing the scenarios and settings in which to use the topical immunomodulator is key in achieving successful, safe treatment outcomes.


View Results